Clinical Trial Update: Post-Licensure Safety Study of ISENTRESS™ (Raltegravir) in a United States Managed Care Network (MK-0518-268)

View source ↗

Summary

A post-licensure safety study of raltegravir (ISENTRESS) in a United States managed care network has completed with results posted in 2016.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Isentress (Raltegravir)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: HIV-1 Infections | Status: COMPLETED | Results posted: 2016-04-07